112 related articles for article (PubMed ID: 3583222)
1. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy.
Legler UF
Horm Metab Res; 1987 Apr; 19(4):168-70. PubMed ID: 3583222
[TBL] [Abstract][Full Text] [Related]
2. Impairment of prednisolone disposition in patients with Graves' disease taking methimazole.
Legler UF
J Clin Endocrinol Metab; 1988 Jan; 66(1):221-3. PubMed ID: 3335606
[TBL] [Abstract][Full Text] [Related]
3. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
4. Methylprednisolone increases plasma leptin levels in Graves' hyperthyroidism patients with active Graves' ophthalmopathy.
Song YM; Lee WJ; Chen MD; Kao CH; Sheu WH
Horm Metab Res; 2000 Jul; 32(7):277-82. PubMed ID: 10965934
[TBL] [Abstract][Full Text] [Related]
5. Detectable serum IgE levels in Graves' ophthalmopathy.
Molnár I; Horváth S; Balázs C
Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
[TBL] [Abstract][Full Text] [Related]
6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
7. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
Bednarek J; Wysocki H; Sowiński J
Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese.
Kamizono S; Hiromatsu Y; Seki N; Bednarczuk T; Matsumoto H; Kimura A; Itoh K
Clin Endocrinol (Oxf); 2000 Jun; 52(6):759-64. PubMed ID: 10848881
[TBL] [Abstract][Full Text] [Related]
9. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
10. E-rosette formation in Graves' ophthalmopathy.
Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ
Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
[TBL] [Abstract][Full Text] [Related]
11. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
[TBL] [Abstract][Full Text] [Related]
12. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
13. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy.
Ozata M; Uckaya G; Bolu E; Corapcioglu D; Bingol N; Ozdemir IC
Med Sci Monit; 2001; 7(4):696-700. PubMed ID: 11433197
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
Brauer VF; Scholz GH
Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
Molnár I; Balázs C
Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
[TBL] [Abstract][Full Text] [Related]
18. Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves' disease.
Izumi M; Larsen PR
J Clin Invest; 1977 Jun; 59(6):1105-12. PubMed ID: 577211
[TBL] [Abstract][Full Text] [Related]
19. Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM).
Ozawa Y; Migita M; Watanabe T; Okuda I; Takeshita A; Takagi A; Shishiba Y
Intern Med; 1994 Sep; 33(9):564-8. PubMed ID: 8000111
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
Mourits MP; Prummel MF; Wiersinga WM; Koornneef L
Clin Endocrinol (Oxf); 1997 Jul; 47(1):9-14. PubMed ID: 9302365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
